Amino-terminal Pro-B-Type natriuretic peptide among patients living with both human immunodeficiency virus and heart failure

2Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background. Among persons living with human immunodeficiency virus (PHIV), incident heart failure (HF) rates are increased and outcomes are worse; however, the role of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations among PHIV with HF has not been characterized. Methods. Patients were derived from a registry of those hospitalized with HF at an academic center in a calender year. We compared the NT-proBNP concentrations and the changes in NT-proBNP levels between PHIV with HF and uninfected controls with HF. Results. Among 2578 patients with HF, there were 434 PHIV; 90% were prescribed antiretroviral therapy and 62% were virally suppressed. As compared to controls, PHIV had higher admission (3822 [IQR, 2413-7784] pg/ml vs 5546 [IQR, 3257-8792] pg/ml, respectively; P

Cite

CITATION STYLE

APA

Alvi, R. M., Zanni, M. V., Neilan, A. M., Hassan, M. Z. O., Tariq, N., Zhang, L., … Neilan, T. G. (2020). Amino-terminal Pro-B-Type natriuretic peptide among patients living with both human immunodeficiency virus and heart failure. Clinical Infectious Diseases, 71(5), 1306–1315. https://doi.org/10.1093/cid/ciz958

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free